AngioDynamics/$ANGO
1D1W1MYTD1Y5YMAX
Capital at risk
About AngioDynamics
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.
- Ticker
- $ANGO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 632
- Headquarters
- Latham, United States
- Website
- www.angiodynamics.com
AngioDynamics Metrics
BasicAdvanced
$641M
-
-$0.88
0.34
-
Price and volume
Market cap
$641M
Beta
0.34
52-week high
$16.29
52-week low
$9.39
Average daily volume
388K
Financial strength
Current ratio
2.187
Quick ratio
1.37
Long term debt to equity
0.054
Total debt to equity
0.064
Interest coverage (TTM)
-77.48%
Profitability
EBITDA (TTM)
0.188
Gross margin (TTM)
54.62%
Net profit margin (TTM)
-11.48%
Operating margin (TTM)
-7.02%
Effective tax rate (TTM)
-1.22%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-5.29%
Return on equity (TTM)
-20.77%
Valuation
Price to revenue (TTM)
2.012
Price to book
3.79
Price to tangible book (TTM)
6.24
Price to free cash flow (TTM)
1,267.882
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.012
Growth
Revenue change (TTM)
9.46%
Earnings per share change (TTM)
6.34%
3-year revenue growth (CAGR)
-1.86%
10-year revenue growth (CAGR)
-0.93%
3-year earnings per share growth (CAGR)
-12.70%
10-year earnings per share growth (CAGR)
-3.08%
What the Analysts think about AngioDynamics
Analyst ratings (Buy, Hold, Sell) for AngioDynamics stock.
Analyst projections of the future price of AngioDynamics stock.
Bulls say / Bears say
Med Tech momentum is strong: FY2026 Med Tech revenue increased 18.4%, marking the company’s seventh consecutive quarter of double-digit Med Tech growth; adjusted EBITDA also improved to $13.2 million from $7.6 million. (AngioDynamics)
NanoKnife offers a meaningful growth catalyst: Q4 NanoKnife sales rose 64.5%, capital sales increased 132.5%, and a Medicare local coverage determination for qualifying prostate and liver cancer cases became effective July 5, 2026. (AngioDynamics)
The clinical and regulatory pipeline is expanding, including FDA IDE approvals for AlphaReturn and the RELIEF BPH study, plus expanded NanoKnife international indications; the company also ended FY2026 with $53.9 million in cash. (SEC)
AngioDynamics remains unprofitable: FY2026 GAAP net loss widened to $36.7 million from $34.0 million, while adjusted net loss was still $10.0 million. (SEC)
Growth is uneven outside Med Tech: Q4 FY2026 Med Device sales rose only 1.1%, while mechanical thrombectomy declined 1.1% as AngioVac sales fell 15.8%. (AngioDynamics)
Margin and pricing risks remain material: tariffs reduced FY2026 gross margin by 151 basis points, while the company also faces intense competition, greater health-system purchasing power and reimbursement pressure. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
AngioDynamics Financial Performance
Revenues and expenses
AngioDynamics Earnings Performance
Company profitability
Upcoming events
No upcoming events
AngioDynamics News
AllArticlesVideos
Funds containing AngioDynamics
Fund name | Fund size | $ANGO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.